课题基金 / 基金详情

IDIOTYPE VACCINATION AFTER BONE MARROW TRANSPLANTATION FOR B CELL MALIGNANCIES

IDIOTYPE VACCINATION AFTER BONE MARROW TRANSPLANTATION FOR B CELL MALIGNANCIES
B 细胞恶性肿瘤骨髓移植后的独特型疫苗接种
批准号:
6395677
负责人:
RONALD LEVY
金额:
$22.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-03-13 至 2001-01-31

项目摘要

项目成果

RONALD LEVY的其他基金

相似基金

相关文献

中文摘要
翻译
在这个项目中,我们建议治疗B细胞恶性肿瘤患者 (多发性骨髓瘤或低度淋巴瘤)伴骨髓 移植后尝试诱导免疫反应 对抗肿瘤 基于我们之前的工作,我们将使用 免疫球蛋白独特型产生的每个患者的肿瘤作为 特异性抗原我们将利用一种新的方法, 我们用分离的树突状细胞 作为抗原呈递细胞。 每一位患者都将 由他/她的肿瘤产生的免疫球蛋白被分离和纯化, 用作疫苗。 将给予高剂量放疗/化疗 患者将接受骨髓或外周血 祖细胞移植 如果一个合适的同胞捐赠者 如果有条件的话,异基因移植将是首选。 后 从移植程序中恢复树突细胞将是 通过白细胞分离术从供体(如果存在)获得,或 从病人身上。 这些细胞将与独特型脉冲 蛋白质,然后在两个场合注入病人, 通过每月注射一系列独特型蛋白, 载体蛋白并与佐剂混合。 患者将 评估他们对肿瘤的免疫反应,我们将 将接受同种异体树突状细胞的患者与 接受自体树突细胞 将设计特殊的检测试剂盒 用于检测针对肿瘤的细胞毒性T细胞 独特型 这个项目提出的基本问题是,有效的反- 肿瘤免疫应答可在患者中诱导B细胞 可以增强高剂量治疗效果的恶性肿瘤 放疗/化疗后进行同种异体或自体造血 前体细胞移植 尽管我们将观察 临床结果的移植演习,拟议的研究是 不是为了证明临床疗效。 主要终点将 是我们希望能够 通过同种异体或自体树突状细胞增强。 如果初始 试点试验显示了有希望的结果,适当的前瞻性研究 将被设计来证明这种新方法的有效性。
英文摘要
In this project we propose to treat patients with B cell malignancies (multiple myeloma or low grade lymphoma) with bone marrow transplantation followed by an attempt to induce an immune response against the tumor. Based on our prior work we will be using the immunoglobulin idiotype produced by each patient's tumor as the specific antigen. We will be taking advantage of a new method of immunization that we have developed using dendritic cells isolated from the blood as antigen presenting cells. Each patient will have the immunoglobulin produced by his/her tumor isolated and purified for use as a vaccine. High dose radio/chemotherapy will be administered and the patients will receive bone marrow or peripheral blood progenitor cell transplants. If a suitable matched sibling donor is available, allogeneic transplantation will be preferred. After recovery from the transplant procedure dendritic cells will be obtained by leukopheresis either from the donor, if one exists, or from the patient. These cells will be pulsed with the idiotype protein and then infused into the patient on two occasions, followed by a series of monthly injections of idiotype protein coupled to a carrier protein and mixed with an adjuvant. The patients will be evaluated for their immune response against the tumor and we will compare the patients receiving allogeneic dendritic cells to those receiving autologous dendritic cells. Special assays will be designed for the detection of cytotoxic T-cells directed against the tumor idiotype. The basic question posed in this project is whether an effective anti- tumor immune response can be induced in patients with B cell malignancies which can augment the therapeutic effect of high dose radio/chemotherapy followed by allogeneic or autologous hematopoietic precursor cell transplantation. Although we will be observing the clinical outcome of the transplant maneuver, the proposed studies are not designed to prove clinical efficacy. The primary endpoints will be the documentation of immune responses which we hope will be enhanced by allogeneic or autologous dendritic cells. If the initial pilot trials show promising results, appropriate prospective studies will be designed to demonstrate the efficacy of this novel approach.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy
  • 批准号:
    10620636
  • 项目类别:
  • 资助金额:
    $51.5万
  • 财政年份:
    2020
  • 负责人:
    RONALD LEVY
  • 依托单位:
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy
  • 批准号:
    10394950
  • 项目类别:
  • 资助金额:
    $51.24万
  • 财政年份:
    2020
  • 负责人:
    RONALD LEVY
  • 依托单位:
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy
  • 批准号:
    10237935
  • 项目类别:
  • 资助金额:
    $52.25万
  • 财政年份:
    2020
  • 负责人:
    RONALD LEVY
  • 依托单位:
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
  • 批准号:
    10229582
  • 项目类别:
  • 资助金额:
    $84.93万
  • 财政年份:
    2016
  • 负责人:
    RONALD LEVY
  • 依托单位:
海外基金